Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
AOD-9604 has superior plasma stability (longer half-life) and is the only fragment that completed Phase 2b clinical trials in obesity
Patients have also occasionally experienced thyroid tumors
It is irresponsible and can lead patients with low B12 to lifelong nerve damage
How AOD-9604 Works (in Brief) AOD-9604 was engineered from the C-terminal segment of human growth hormone (amino acids 177191) the portion thought to influence fat metabolism. In preclinical models, this fragment supported fat oxidation and lipid mobilization without the broader hormonal effects of full-length hGH. Because it does not activate the traditional hGH receptor, its fat-metabolism effects are considered indirect and receptor-independent. Discovery & Research Milestones Originally developed in the 1990s as a potential anti-obesity drug
US$ 25.81
US$ 27.09
US$ 20.61
US$ 26.56
US$ 22.48
US$ 23.18
